RTsafe news

RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom, today announced the purchase of two RTsafe PRIME phantoms. These are the first PRIME phantoms to be installed in Aus

RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in German

ATHENS, Greece, November 24, 2021  

Following our successful cooperation since 2018, we are excited to announce that RTsafe and Medical Physics Limited expand their cooperation by entering into a partnership agreement under which Medical Physics Limited will be the agent of RTsafe’s innovative solutions for quality assurance in radiotherapy in the United Kingdom. Moreover, our partnership agreement is extended towards supporting selected global projects.

RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China.

We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese radiotherapy

RTsafe launches the Dosimetry Audit Service – succeSRS

The complex nature of the stereotactic treatment process demands commitment to the highest levels of accuracy and precision. That being the case we are thrilled to announce the launch of our new dosimetry audit service aiming to promote a culture of excellence.